Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5'-nucleotidase (CD73) is a glycosylphosphatidylinositol (GPI)-anchored cell surface enzyme that plays a pivotal role in the purinergic signaling pathway by catalyzing the conversion of extracellular adenosine monophosphate (AMP) to adenosine [1, 2]. When localized on or within mesenchymal stem cell-derived extracellular vesicles (MSC-EVs), CD73 acts as a primary mediator of the immunomodulatory and regenerative properties of these cell-free therapeutic agents [3]. The enzymatic activity of CD73 on the EV surface facilitates the production of adenosine, which binds to P1 receptors (specifically A2A and A2B) on target cells to suppress pro-inflammatory cytokine production and promote an M2-like anti-inflammatory macrophage phenotype [4, 5]. This mechanism has been extensively studied in the context of myocardial ischemia-reperfusion injury, where MSC-EV-associated CD73 significantly reduces infarct size and promotes cardiac repair [3, 6]. While CD73 is a prominent target for monoclonal antibodies and small molecule inhibitors in oncology to prevent adenosine-mediated immune evasion, its presence on MSC-EVs is leveraged for therapeutic benefit in inflammatory and ischemic diseases [7, 8]. The characterization of CD73 activity is often used as a potency assay for MSC-EV products, making it a critical biomarker for manufacturing and efficacy monitoring [9]. Sources: [1] UniProt P21589; [2] Zimmermann H. (1992) Biochem J; [3] Lai RC, et al. (2010) Stem Cell Res; [4] Antonioli L, et al. (2013) Nat Rev Cancer; [5] Zhang S, et al. (2016) Osteoarthritis Cartilage; [6] Arslan F, et al. (2013) Stem Cell Res; [7] Bongiovanni L, et al. (2021) Front Immunol; [8] Arcus Biosciences Pipeline; [9] Willis GR, et al. (2017) Stem Cells Transl Med.
Hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, which subsequently activates P1 receptors (A2A and A2B) to modulate immune cell activity and promote tissue regeneration.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5'-nucleotidase (CD73) on mesenchymal stem cell-derived extracellular vesicles (CD73-MSC-EV).